Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06569602

Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)

Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) — Recruiting • Cardiology / Cardiovascular • NCT06569602.

📅 04 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06569602
Sponsor
Edwards Lifesciences
Start
2024-10-01
ClinicaliQ Trial Snapshot
  • Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) — Recruiting • Cardiology / Cardiovascular • NCT06569602.
  • What is being tested: The Edwards EVOQUE system is undergoing real-world safety and clinical efficacy evaluation across multiple European centres in a prospective, single-arm study design.
  • Patient eligibility overview: This real-world investigation enrolls patients meeting criteria for the EVOQUE system; specific eligibility parameters would be detailed in the full protocol but typically include patients with appropriate cardiac anatomy and clinical indication for the intervention.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is a prospective, single-arm, multi-center, real-world study of an the Edwards EVOQUE system.

Eligibility Snapshot
  • : 1. The Local Site Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement with the EVOQUE system per the current instructions for use.
  • Patient agrees to attend follow-up assessments. 3. Patients provided written informed consent for participation in the study.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Meet the teenagers calling for action on violence against women and girls
Cardiology / Cardiovascular · BBC Health · 28 Jul 2026
Teenage activists are mobilising public engagement on violence against women and girls (VAWG), highlighting widespread concern among younger generations about this health…
View brief →
Guideline
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Cardiology / Cardiovascular · 16 Jul 2026
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or…
View guideline →
Guideline
EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure
Cardiology / Cardiovascular · 30 Mar 2026
This EMA guideline addresses EMA Guideline on Clinical Investigation of Medicinal Products for Heart Failure in Cardiology / Cardiovascular. Use it to…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Sotatercept for treating pulmonary arterial hypertension
Cardiology / Cardiovascular · 03 Jun 2026
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and…
View guideline →